Catalyst
Slingshot members are tracking this event:
Merrimack Pharmaceuticals (MACK) initiates Phase 1 study of MM-310 in solid tumors, looking to extract appropriate dosage for Phase 2
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| MACK | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 31, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Mm-310, Solid Tumors, Phase 1
